fluorouracil has been researched along with Hepatitis C in 9 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 7.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
| "We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)." | 7.79 | [Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013) |
| "We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches." | 7.73 | Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005) |
| "Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 3.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
| "We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)." | 3.79 | [Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013) |
| "We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches." | 3.73 | Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005) |
| "The prognosis of advanced hepatocellular carcinoma (HCC) is extremely poor." | 1.32 | [A report of two cases--two patients of the extremely advanced hepatocellular carcinoma have responded completely for a long time after a combination therapy consisting of arterial chemotherapy and injection of interferon-alpha]. ( Danno, M; Dono, K; Hatanaka, T; Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Monden, M; Nagano, H; Nakamori, S; Naoi, Y; Ohshima, S; Sakon, M; Tsujie, M; Umeshita, K; Yamamoto, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fushiya, N | 1 |
| Takagi, I | 1 |
| Nishino, H | 1 |
| Akizuki, S | 1 |
| Ohnishi, A | 1 |
| Tsuda, Y | 1 |
| Kobayashi, S | 1 |
| Tomimaru, Y | 1 |
| Akita, H | 1 |
| Hama, N | 1 |
| Wada, H | 2 |
| Kawamoto, K | 1 |
| Eguchi, H | 2 |
| Umeshita, K | 3 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Nagano, H | 3 |
| Lin, JW | 1 |
| Chang, ML | 1 |
| Hsu, CW | 1 |
| Chen, YC | 1 |
| Liang, KH | 1 |
| Huang, YH | 1 |
| Lin, CC | 1 |
| Yeh, CT | 1 |
| Nanashima, A | 1 |
| Tanaka, K | 1 |
| Yamaguchi, H | 1 |
| Shibasaki, S | 1 |
| Morino, S | 1 |
| Yoshinaga, M | 1 |
| Sawai, T | 1 |
| Nakagoe, T | 1 |
| Ayabe, H | 1 |
| Iijima, S | 1 |
| Kikkawa, N | 1 |
| Kurokawa, E | 1 |
| Yamamoto, H | 1 |
| Kato, T | 1 |
| Tsujie, M | 1 |
| Ohshima, S | 1 |
| Hayashi, T | 1 |
| Naoi, Y | 1 |
| Hatanaka, T | 1 |
| Danno, M | 1 |
| Sakon, M | 2 |
| Dono, K | 2 |
| Nakamori, S | 2 |
| Monden, M | 2 |
| Melisko, ME | 1 |
| Fox, R | 1 |
| Venook, A | 1 |
| Ota, H | 1 |
| Kondo, M | 1 |
| Yamamoto, T | 1 |
| Nakamura, M | 1 |
| Damdinsuren, B | 1 |
| Marubashi, S | 1 |
| Miyamoto, A | 1 |
| Wakasa, K | 1 |
| Berretta, M | 1 |
| Lleshi, A | 1 |
| Di Benedetto, F | 1 |
| Bearz, A | 1 |
| Spina, M | 1 |
| Tirelli, U | 1 |
| Sato, Y | 1 |
| Ichida, T | 1 |
| Ito, S | 1 |
| Hatakeyama, K | 1 |
9 other studies available for fluorouracil and Hepatitis C
| Article | Year |
|---|---|
Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; C | 2013 |
[Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy].
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, The | 2013 |
Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Drug Therapy; Female; Fluorouraci | 2017 |
Fibrosis and inflammatory activity in noncancerous tissue and mitotic index of cancer tissue in patients with hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; F | 2003 |
[A report of two cases--two patients of the extremely advanced hepatocellular carcinoma have responded completely for a long time after a combination therapy consisting of arterial chemotherapy and injection of interferon-alpha].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy | 2003 |
Reactivation of hepatitis C virus after chemotherapy for colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Fl | 2004 |
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Prog | 2005 |
Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Capeci | 2006 |
Preoperative administration of 5-FU and interferon beta may prevent recurrence of hepatitis B and C virus.
Topics: Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluorouracil | 2002 |